<--- Back to Details
First PageDocument Content
Medicine / Tuberculosis treatment / Mantoux test / Latent tuberculosis / Mycobacterium tuberculosis / Nontuberculous mycobacteria / Case definition / Tuberculosis diagnosis / Tuberculosis in China / Tuberculosis / Bacteria / Microbiology
Date: 2013-06-20 02:49:09
Medicine
Tuberculosis treatment
Mantoux test
Latent tuberculosis
Mycobacterium tuberculosis
Nontuberculous mycobacteria
Case definition
Tuberculosis diagnosis
Tuberculosis in China
Tuberculosis
Bacteria
Microbiology

GUIDELINES ON NOTIFICATION OF TUBERCULOSIS (TB)

Add to Reading List

Source URL: www.chp.gov.hk

Download Document from Source Website

File Size: 50,08 KB

Share Document on Facebook

Similar Documents

For immediate release March 21, 2017 Infectex Announces Positive Phase 2b-3 Clinical Trial Results of SQ109 for the Treatment of Multidrug-Resistant Pulmonary Tuberculosis Moscow, Russia and Rockville, MD, USA -- Infecte

DocID: 1vkmw - View Document

PRESS RELEASE Adequate treatment essential to stop TB across Europe – new ECDC/WHO report Stockholm/Copenhagen, 19 MarchOverpatients are estimated to fall sick with tuberculosis (TB) every day across Euro

DocID: 1saSR - View Document

JOINT PRESS RELEASE New ECDC-WHO report: tuberculosis on the retreat in Europe. Concerns about drugresistant TB and treatment failure. Stockholm/Copenhagen, 19 March 2012

DocID: 1rHnT - View Document

Tuberculosis / Medicine / Clinical medicine / Health / Tuberculosis management / Tuberculosis diagnosis / DOTS / World Tuberculosis Day / TB Alert / Tuberculosis in India

15 | P a g e Multiple healthcare Seeking behaviors of new Smear positive pulmonary tuberculosis patients attending a diagnosis and treatment center of Bafoussam- Cameroon ABSTRACT FABRICE NEMBOT DJOUMA , ARMELLE VIVIAN

DocID: 1qzgC - View Document

Tuberculosis / Clinical medicine / Health / Medicine / Multi-drug-resistant tuberculosis / Bedaquiline / Tuberculosis management / Latent tuberculosis

Embargoed: 12 May – 1130 hrs CEST WORLD HEALTH ORGANIZATION RECOMMENDS SHORTENED NINE-MONTH TREATMENT REGIMEN FOR MDR-TB PATIENTS

DocID: 1q2l5 - View Document